陕国投A(000563) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥714,644,500.25, an increase of 18.35% compared to ¥603,817,495.84 in the same period last year[4] - Net profit attributable to shareholders for Q1 2024 was ¥367,597,039.98, reflecting a growth of 10.03% from ¥334,076,443.11 in Q1 2023[4] - The company reported a total comprehensive income of ¥367,597,039.98, compared to ¥334,076,443.11 in the previous period[32] - Basic and diluted earnings per share increased to ¥0.0719 from ¥0.0653, reflecting a growth of 10.1%[32] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net amount of -¥211,066,171.50, a 75.04% increase compared to -¥845,702,221.85 in the previous year[4] - Cash outflow from investment activities totaled 2,380,339,087.83, with a net cash flow from investment activities of -192,507,358.15[36] - Cash inflow from financing activities amounted to 682,100,000.00, while total cash outflow from financing activities was 1,215,144,588.33, resulting in a net cash flow from financing activities of -533,044,588.33[36] - The net increase in cash and cash equivalents was -936,618,117.98, leading to an ending balance of 494,112,413.54[36] - The beginning balance of cash and cash equivalents was 1,430,730,531.52, indicating a significant decrease in liquidity[36] Assets and Liabilities - Total assets as of March 31, 2024, reached ¥24,978,781,770.46, marking a 3.93% increase from ¥24,034,170,948.98 at the end of the previous year[4] - The total liabilities increased to CNY 7,522,189,769.15 from CNY 6,945,175,987.65[23] - The company's equity totaled CNY 17,456,591,001.31, reflecting the difference between total assets and total liabilities[23] - The total equity attributable to shareholders increased by 2.15% to ¥17,456,592,001.31 from ¥17,088,994,961.33 at the end of the previous year[4] Income Sources - The company reported a 39.04% increase in net commission and fee income, totaling ¥380,938,712.27 compared to ¥273,968,388.08 in Q1 2023[11] - Investment income surged by 49.48%, reaching ¥212,256,808.51, up from ¥141,998,496.63 in the same quarter last year[11] - Net interest income decreased to ¥106,649,219.75, down 25.3% from ¥142,827,849.02 in the previous period[27] Shareholder Information - The company has no new shareholders entering or exiting the top 10 list during the reporting period[17] - The company’s major shareholder, Shaanxi Nuclear Medicine Development Partnership, holds 45,557,846 shares, representing 0.89% of the total share capital[17] - The company reported no changes in the financing and securities lending activities of its major shareholders[17] Other Financial Metrics - The weighted average return on equity increased to 2.13%, up by 0.09 percentage points from 2.04% in the previous year[4] - The company experienced a significant increase in credit impairment losses, which rose by 234.44% to ¥34,502,595.26 from a recovery of -¥25,663,963.06 in Q1 2023[11] - Operating expenses increased to ¥223,594,669.54, up from ¥158,048,345.46 in the previous period[27] - The company's cash and cash equivalents decreased to CNY 494,112,413.54 from CNY 1,430,730,531.52[21] - The company's financial investments rose to CNY 11,863,764,288.46 from CNY 10,573,619,630.81[23] - The debt investment increased to CNY 7,772,727,635.01 from CNY 5,871,788,130.28[23] Audit Status - The company’s first quarter report was not audited, which may impact the reliability of the financial data presented[37]